Related by context. All words. (Click for frequent words.) 74 ganetespib 72 INCB# [001] 72 obatoclax 72 voreloxin 72 OXi# 70 Cloretazine R VNP#M 70 pomalidomide 70 ZYBRESTAT 70 HGS ETR1 70 registrational trial 70 alvespimycin 69 enzastaurin 69 pralatrexate 69 PXD# 69 Panzem R NCD 69 axitinib 69 phase IIb clinical 69 CA4P 69 PEG SN# 69 Cloretazine 68 deforolimus 68 tesetaxel 68 tesmilifene 68 CR# vcMMAE 68 tanespimycin 68 FOLOTYN 68 forodesine 68 perifosine 68 elotuzumab 68 RDEA# 68 HGS# 68 EndoTAG TM -1 68 eniluracil 68 decitabine 67 ELACYT 67 Amigal 67 Targretin 67 MGCD# [001] 67 picoplatin 67 adecatumumab 67 Phase Ib II 67 lintuzumab 67 Symadex 67 glufosfamide 67 PROSTVAC TM 67 CYT# 67 vicriviroc 67 Amrubicin 67 sunitinib malate 67 CoFactor 67 ixabepilone 67 T DM1 67 HGS ETR2 67 ofatumumab 66 Phase Ib study 66 Sym# 66 tezampanel 66 belinostat 66 ponatinib 66 AEG# 66 AP# [003] 66 XL# [003] 66 IMC A# 66 pertuzumab 66 BAY #-# 66 MOZOBIL 66 romidepsin 66 Cloretazine ® 66 aflibercept 66 oral ridaforolimus 66 R#/MEM # 66 BRIM2 66 OncoVEX GM CSF 65 vorinostat 65 rNAPc2 65 seliciclib 65 elacytarabine 65 otelixizumab 65 celgosivir 65 Phase Ib 65 vandetanib 65 phase IIa clinical 65 PRT# 65 TELCYTA 65 RIGScan CR 65 monotherapy 65 BCX# 65 custirsen 65 randomized Phase 2b 65 mapatumumab 65 GALNS 65 vascular disrupting agent 65 sorafenib Nexavar ® 65 TBC# 65 Genasense 65 Omacetaxine 65 palifosfamide 65 dasatinib 65 Asentar 65 HuLuc# 65 anti leukemic 65 eltrombopag 65 nab paclitaxel 65 TELINTRA 65 OvaRex R 65 nitazoxanide 65 Phase #b/#a 64 GRN#L 64 docetaxel chemotherapy 64 registrational 64 XmAb# 64 talabostat 64 Ceflatonin 64 PSMA ADC 64 lesinurad 64 vidofludimus 64 Marqibo 64 RGB # 64 PEG Interferon lambda 64 ASA# 64 Phase 1b 64 epigenetic therapies 64 Xanafide 64 clofarabine 64 paclitaxel Taxol ® 64 daclizumab 64 MGCD# [002] 64 valopicitabine 64 blinatumomab 64 Azedra 64 OMAPRO 64 Fludara 64 Alocrest 64 bosutinib 64 phase IIb 64 thymalfasin 64 ongoing Phase 1b 64 ADVEXIN 64 carfilzomib 64 neratinib 64 elesclomol 64 HER2 positive metastatic breast 64 RG# [001] 64 Archexin 64 Tarceva TM 64 Azixa 64 L BLP# 64 OPAXIO 64 IMA# 64 Allovectin 7 ® 64 HRPC 64 panitumumab 64 Phase 2b trial 64 Jevtana 64 Panzem R 64 galiximab 64 OvaRex ® MAb 64 Azedra TM 63 Sapacitabine 63 azacitidine 63 amrubicin 63 brentuximab vedotin SGN 63 PLX# 63 HuMax CD4 63 Traficet EN 63 IMGN# 63 vemurafenib 63 metaglidasen 63 Phase 2b clinical 63 Cloretazine R 63 INCB# [002] 63 atacicept 63 Vilazodone 63 subcutaneous PRO 63 Imprime PGG 63 PDE4 inhibitor 63 Chemophase 63 PRX # 63 Blinatumomab 63 Allovectin 7 63 radiation sensitizer 63 MEK inhibitor RDEA# 63 Zybrestat 63 VEGF Trap 63 Viramidine 63 talactoferrin 63 plus gemcitabine 63 JAK inhibitors 63 ASONEP 63 TG# [003] 63 Phenoptin 63 Dacogen injection 63 Elotuzumab 63 lupus nephritis 63 mRCC 63 Bortezomib 63 cangrelor 63 evaluating tivozanib 63 Phase 2a trial 63 OncoVEX 63 torezolid phosphate 63 eculizumab 63 Bezielle 63 CYC# 63 Exelixis XL# 63 teriflunomide 63 Abiraterone acetate 63 Zerenex 63 ISIS # 63 receptor tyrosine kinase inhibitor 63 Voreloxin 63 vosaroxin 63 Onrigin 63 DR Cysteamine 63 relapsed refractory multiple myeloma 63 Phase IIb trials 63 docetaxel Taxotere R 63 crizotinib PF # 63 IRX 2 63 FOLOTYN ® 63 phase IIa 63 omacetaxine 63 generation purine nucleoside 63 ENMD # 63 BRAF inhibitor 63 dose cohorts 63 MDV# 63 sorafenib Nexavar 63 PI3K/Akt pathway inhibitor 63 cutaneous T cell 63 lapatinib Tykerb 63 PSN# [002] 63 Tasimelteon 63 FTY# 63 initiate Phase 1b 63 zalutumumab 63 Torisel 62 CCX# 62 vinorelbine 62 Allovectin 7 R 62 ProLindac 62 phase Ib 62 CIMZIA TM 62 Tesetaxel 62 OMP #M# 62 L MTP PE 62 HQK 62 Phase 1b trial 62 seliciclib CYC# 62 trabedersen 62 Intravenous CP 62 cilengitide 62 Pivotal Phase 62 Plicera 62 KRN# 62 Ophena TM 62 Dasatinib 62 JAK inhibitor 62 HCV protease inhibitor 62 Virulizin ® 62 dose escalation 62 ruxolitinib 62 rindopepimut 62 DXL# 62 unresectable stage 62 veltuzumab 62 low dose cytarabine 62 relapsed multiple myeloma 62 CEQ# 62 Phase IIb clinical trials 62 R roscovitine 62 Perifosine 62 Phase #/#a trial 62 YONDELIS 62 Triapine R 62 anticancer compound 62 PNP inhibitor 62 TREANDA 62 angiogenesis inhibitor 62 Restanza 62 phase IIb trial 62 CBLC# 62 IAP inhibitors 62 TNFerade 62 Proxinium TM 62 Cotara 62 bortezomib 62 LymphoStat B 62 Atiprimod 62 metastatic castration resistant 62 huC# DM4 62 Tyrima 62 REOLYSIN ® 62 TOLAMBA 62 Taxotere ® 62 lymphoma CTCL 62 nilotinib 62 abiraterone acetate 62 mipomersen 62 double blinded placebo 62 Phase 2b 62 CLORETAZINE TM VNP#M 62 IMC #B 62 bicifadine 62 Clolar 62 EndoTAGTM 1 62 antitumor activity 62 Alzhemed TM 62 VNP#M 62 MGd 62 ZYBRESTAT fosbretabulin 62 Revlimid lenalidomide 62 rALLy clinical trial 62 SCH # 62 imetelstat 62 HuMax EGFr 62 vilazodone 62 PS# [001] 62 docetaxel 62 refractory acute myeloid 62 uric acid lowering 62 dacetuzumab 62 Phase Ib clinical 62 favorable pharmacokinetic profile 62 XL# SAR# 62 cediranib 62 TRISENOX 62 ENMD 62 Phase IIB 62 bosentan 62 Annamycin 62 trastuzumab DM1 T DM1 62 epothilone 62 liposomal formulation 62 ridaforolimus 62 Doxil 62 MAGE A3 ASCI 62 JVRS 62 Romidepsin 62 carboplatin paclitaxel 62 tezampanel NGX# 62 gefitinib Iressa 62 systemic ALCL 62 velafermin belinostat 61 tasimelteon 61 pan HDAC inhibitor 61 radezolid 61 Bicifadine 61 anticancer agents 61 phase 2a 61 PF # [001] 61 APOPTONE 61 MAXY G# 61 gemcitabine 61 Omnitarg 61 Reverset 61 NVA# 61 brivaracetam 61 samalizumab 61 CYT# potent vascular disrupting 61 LY# [003] 61 preclinically 61 Seliciclib 61 EOquin TM 61 NEUMUNE 61 confirmatory Phase III 61 dose cohort 61 JAK1 61 DAVANAT R 61 SILENOR TM 61 LUX Lung 61 ISTODAX 61 SUTENT 61 multitargeted 61 Genz # 61 visilizumab 61 Aurora kinase 61 Panzem 61 Trastuzumab 61 ELND# 61 SUCCEED trial 61 Icatibant 61 refractory AML 61 entinostat 61 TTF Therapy 61 NXL# 61 tyrosine kinase inhibitors 61 FOLFOX6 chemotherapy regimen 61 TRO# 61 IIa trial 61 Vion Pharmaceuticals 61 nonclinical studies 61 aflibercept VEGF Trap 61 BLA filing 61 EOquin 61 bendamustine 61 Clolar ® 61 metastatic renal cell 61 anti angiogenic agents 61 TACI Ig 61 platinum refractory 61 Genasense ® oblimersen 61 IL# PE#QQR 61 Civacir 61 Aplidin 61 AEGR 61 Phase III randomized controlled 61 Randomized Phase 61 Evoltra ® 61 DCCR 61 Vitaxin 61 Pertuzumab 61 MEK inhibitors 61 HoFH 61 myelofibrosis 61 unique alkylating agent 61 topotecan 61 Lenocta 61 OMNARIS HFA 61 TLK# 61 PANVAC VF 61 Viprinex 61 Phase IIa trials 61 hormone refractory prostate cancer 61 Taxotere R 61 Technosphere Insulin 61 tocilizumab 61 Treanda 61 relapsed MM 61 Mipomersen 61 Tarvacin TM 61 pivotal Phase 61 trastuzumab Herceptin R 61 figitumumab 61 antithrombotic 61 EGFR inhibitors 61 Dapagliflozin 61 ONTAK 61 oral salmon calcitonin 61 PROSTVAC VF 61 cytarabine 61 afatinib 61 temsirolimus 61 Phase IIa trial 61 pazopanib 61 investigational therapies 61 peginesatide 61 HuMax CD# 61 velafermin 61 dexpramipexole 61 molecularly targeted 61 Nexavar sorafenib 61 tubulin inhibitor 61 bardoxolone 61 maximally tolerated dose 61 placebo controlled Phase 61 dalbavancin 61 MLN# 61 DU #b 61 tivozanib 61 MAP# 61 Apoptone 61 Altastaph 61 RSD# oral 61 Tavocept 61 novel VDA molecule 61 sunitinib 61 viral kinetics 61 Carfilzomib 61 metastatic HRPC 61 XL# XL# XL# 61 relapsed AML 61 taxane 61 CD# CEA 61 mertansine 61 heavily pretreated 61 apremilast 61 ONCONASE R 61 zileuton CR 61 orally administered inhibitor 61 Glufosfamide 61 Phase 2b study 61 bortezomib Velcade R 61 Desmoteplase 61 lixisenatide 61 PhosLo 61 NEUGENE 61 metastatic sarcomas 61 investigational monoclonal antibody 61 relapsed SCLC 61 HCD# [002] 61 Personalized Immunotherapy 61 Talotrexin 61 teduglutide 61 goserelin 61 BCR ABL inhibitor 61 NGX# 61 Tarceva erlotinib 61 APTIVUS 61 TOCOSOL Paclitaxel 61 Herceptin trastuzumab 60 Stedivaze 60 Elagolix 60 Naproxcinod 60 IMiDs 60 metastatic renal cell carcinoma 60 metastatic hormone refractory 60 Panzem NCD 60 kinase inhibitor 60 SLx 60 regorafenib 60 AeroLEF TM 60 leukemia AML 60 Nanobody 60 polymerase inhibitors 60 placebo controlled Phase III 60 zanolimumab 60 CRx 60 NPSP# 60 Opexa 60 GAMMAGARD 60 Fx #A 60 CD# antibody [001] 60 sargramostim 60 Advexin 60 Pivotal Phase III 60 PEG PAL 60 hour bronchodilation 60 brentuximab vedotin 60 SinuNase 60 Hepatocellular Carcinoma HCC 60 generation Hsp# inhibitor 60 Vidaza 60 alemtuzumab Campath 60 AQ4N 60 MEK inhibitor 60 Albuferon 60 CCR5 antagonist 60 Aurexis 60 TORISEL 60 Serdaxin 60 Factor VIIa 60 RLY# 60 novel anticancer 60 sorafenib tablets 60 fosbretabulin 60 MAA submission 60 XL# XL# 60 MYDICAR ® 60 baminercept 60 Spiro Rombotis President 60 leading oral taxane 60 GRN# 60 G CSF 60 huN# DM1 60 GVAX 60 viral kinetic 60 cytotoxic chemotherapy 60 cell lymphoma CTCL 60 vascular disrupting agents 60 pegylated liposomal doxorubicin 60 nalbuphine ER 60 gemcitabine cisplatin 60 kinase inhibitors 60 randomized Phase III 60 MoxDuo IR 60 Neuradiab 60 infusional 5-FU/LV 60 castration resistant prostate cancer 60 GMX# 60 sorafenib 60 integrase inhibitor 60 Corlux 60 Phase III Pivotal 60 Nexavar ® 60 AMD# [003] 60 LHRH antagonists 60 ZOLINZA 60 ARIKACE ™ 60 gemcitabine Gemzar ® 60 CTAP# Capsules 60 EFAPROXYN 60 Locteron ® 60 orBec 60 INT# [002] 60 Locteron 60 ularitide 60 GAP #B# 60 Insegia 60 olaparib 60 urocortin 2 60 randomized Phase 60 Pimavanserin 60 dirucotide 60 ostarine 60 EVIZON 60 Hsp# inhibitor 60 GATTEX 60 Golimumab 60 triphendiol 60 estramustine 60 Neulasta ® 60 Talabostat 60 xenograft models 60 SNT MC# 60 ZYBRESTAT TM 60 TKM ApoB 60 ganaxolone 60 lumiliximab 60 AZILECT R 60 darapladib 60 Reolysin 60 Ozarelix 60 XYOTAX 60 velaglucerase alfa 60 mTOR inhibitors 60 farletuzumab 60 Zerenex ™ 60 Nasulin 60 Tovaxin 60 Androxal 60 pharmacodynamic properties 60 alvimopan 60 ocrelizumab 60 iclaprim 60 Ostarine 60 selective androgen receptor modulator 60 anticancer agent 60 refractory chronic lymphocytic 60 GRNVAC1 60 oblimersen 60 fluoropyrimidine 60 tenofovir emtricitabine 60 Virulizin R 60 THALOMID 60 HspE7 60 GLPG# 60 #ME# 60 PLK1 SNALP 60 oral picoplatin 60 CDK inhibitor 60 elvitegravir 60 Resten NG 60 multicenter Phase II 60 Xyotax 60 histone deacetylase HDAC inhibitor 60 tramiprosate Alzhemed TM 60 adecatumumab MT# 60 oral taxane 60 KNS # 60 cannabinor 60 midstage clinical 60 Q#IR 60 rALLy trial 60 androgen independent 60 tamibarotene 60 Velcade bortezomib 60 bortezomib Velcade 60 hematological malignancies 60 castrate resistant prostate cancer 60 faropenem 60 Quinamed 60 tolevamer 60 Campath alemtuzumab 60 TMC# [002] 60 corticosteroid dexamethasone 60 Phase #b/#a trial 60 PDX pralatrexate 60 RhuDex ® 60 atrasentan 60 tyrosine kinase inhibitor 60 dose escalation Phase 60 BENLYSTA 60 Targretin capsules 60 Aflibercept 60 GLYX 60 Octreolin 60 DermaVir Patch 60 Pralatrexate 60 raltegravir 60 FOLFIRI 60 ipilimumab 60 MyVax R 60 immunomodulatory 60 imatinib Gleevec 60 GW# [003] 60 nucleoside analog 60 ThGRF 60 Menerba 60 Aplidin R 60 polymerase inhibitor 59 advanced NSCLC 59 ataluren 59 tecarfarin 59 pegylated interferon alpha 59 ANA# 59 pegfilgrastim 59 INC# 59 XYOTAX TM 59 oritavancin 59 Stimuvax R 59 AVN# [001] 59 cabazitaxel 59 Phase #b/#a clinical 59 CRLX# 59 Phase 2a 59 PEP# [003] 59 Onrigin TM 59 Exherin TM 59 VAPRISOL 59 Evoltra 59 ALN PCS 59 palifosfamide Zymafos TM 59 dosing cohort 59 nicotinic alpha 7 59 dacarbazine 59 lintuzumab SGN 59 Tanespimycin 59 OHR/AVR# 59 anticancer therapies 59 LymphoStat B belimumab 59 MERLIN TIMI 59 Phase IIIb clinical 59 cutaneous T 59 Ceflatonin R 59 confirmatory clinical 59 refractory Hodgkin lymphoma 59 CCX# B 59 PREZISTA r 59 oral gallium 59 ThermoDox R 59 microtubule targeting 59 secondary efficacy endpoints 59 BZL# 59 TNF alpha inhibitor 59 ALN TTR# 59 LEUKINE 59 oral prodrug 59 hematologic malignancies 59 Actilon 59 IMPACT IMmunotherapy 59 nucleoside 59 Phase 2a clinical 59 CCR9 antagonist 59 posaconazole 59 lenalidomide Revlimid R 59 nucleoside reverse transcriptase inhibitor 59 diabetic neuropathic pain 59 Tezampanel 59 PI3K inhibitor 59 YERVOY 59 dosing regimens 59 TRIOLEX 59 tranilast 59 Soliris TM eculizumab 59 TKB# 59 subcutaneous formulation 59 ISENTRESS 59 Triolex 59 Laquinimod 59 VELCADE 59 daptomycin 59 odanacatib 59 dose escalation phase 59 initiate Phase Ib 59 rhIGFBP 3 59 bevacizumab Avastin 59 daunorubicin 59 pivotal Phase III 59 HDAC Inhibitor 59 cMET 59 ulimorelin 59 Phase III clinical 59 Tamibarotene 59 iniparib 59 ThermoDox 59 plus dexamethasone 59 Degarelix 59 investigational humanized monoclonal antibody 59 NUVIGIL 59 metastatic castrate resistant 59 standard chemotherapy regimen 59 eprotirome 59 ApoB SNALP 59 Genasense ® 59 ONCONASE 59 EZN 59 metastatic CRC 59 PEGPH# 59 carboplatin 59 selective kinase inhibitor 59 Prostate AdenoCarcinoma Treatment 59 remission induction 59 Telaprevir 59 bevacizumab Avastin ® 59 JAK3 59 Doxil ® 59 erlotinib Tarceva ® 59 Zolinza 59 Pazopanib 59 Roche Chugai s 59 Azedra ™ 59 SAR# [004] 59 ADVANCE PD 59 virus HCV protease inhibitor 59 subcutaneously administered 59 μg dose 59 adalimumab Humira 59 thalidomide Thalomid 59 DsiRNA 59 rBChE 59 golimumab 59 calcineurin inhibitors 59 AZD# 59 Troxatyl 59 cetuximab Erbitux 59 Phase IIb 59 Curaxin CBLC# 59 nucleotide analog 59 davunetide intranasal AL 59 proteasome inhibitor 59 APTIVUS r 59 L Annamycin 59 depsipeptide 59 Excellarate 59 Hsp# inhibition 59 ambrisentan 59 AzaSite Plus 59 immunotherapeutic agent 59 Alemtuzumab 59 including eniluracil ADH 59 Celator 59 UVIDEM 59 siRNA therapeutics 59 CCR5 mAb 59 riociguat 59 Clavis Pharma 59 randomized controlled Phase 59 APPRAISE 59 Fabry Disease 59 Phase IIa 59 iSONEP 59 pradefovir 59 Triapine 59 SinuNase TM 59 CBLB# 59 interferon gamma 1b 59 methylnaltrexone 59 GFT# 59 gefitinib 59 TriRima 59 docetaxel Taxotere ® 59 ORENCIA R 59 Valsartan 59 Phase IIb trial 59 oxypurinol 59 MAXY alpha 59 ALKS 59 Inhalation Solution 59 ATL/TV# 59 hA# 59 advanced carcinoid 59 R sorafenib tablets 59 abatacept 59 ospemifene 59 2 methoxyestradiol 59 ATL# [001] 59 evaluating satraplatin 59 clinical pharmacology studies 59 ACTEMRA TM 59 boosted protease inhibitor 59 FOLFOX4 59 cetuximab Erbitux R 59 ozarelix 59 Phase #/#a 59 sodium Injection 59 ON #.Na 59 anidulafungin 59 Urocidin 59 alemtuzumab 59 PROSTVAC ® 59 CANCIDAS 59 rFVIIIFc 59 cabozantinib 59 Hedgehog Pathway Inhibitor 59 orally bioavailable 58 Ambrisentan 58 rFIXFc 58 LCP AtorFen 58 Androxal ® 58 dasatinib Sprycel 58 recurrent NSCLC 58 pemetrexed 58 incyclinide 58 Shigamabs ® 58 RSD# 58 Leukine 58 treprostinil 58 Bronchitol 58 telaprevir 58 CIMZIA ™ 58 Androxal TM 58 Fodosine 58 dimebon 58 Solazed 58 intermittent dosing 58 cetuximab Erbitux ® 58 telbivudine 58 APF# 58 sevelamer 58 tafamidis 58 CMV vaccine 58 UPLYSO 58 zileuton IV 58 Promacta 58 GV# [001] 58 LAF# 58 Defibrotide 58 indolent NHL 58 NSCLC 58 Revimmune 58 BENLYSTA ® 58 trastuzumab emtansine T DM1 58 ZACTIMA 58 nucleoside analogs 58 resminostat 58 chemotherapeutic regimen 58 IMP# 58 oral FTY# 58 placebo controlled clinical 58 BrachySil TM 58 EGFR TKI 58 K ras mutations 58 Vidaza azacitidine 58 Diabetic Macular Edema 58 AKT inhibitor 58 TroVax ® 58 rALLy 58 systemically administered 58 IDX# 58 renin inhibitors 58 FOLFOX 58 sipuleucel T 58 milatuzumab 58 ToGA 58 ZADAXIN 58 maribavir 58 humanized anti 58 lapatinib 58 Diamyd ® 58 SABCS 58 Phase III 58 anti TNF 58 Phase III Clinical Trials 58 antiviral activity 58 refractory multiple myeloma 58 R#/MEM 58 Trofex 58 pharmacodynamic PD 58 rituximab 58 midstage trials 58 ZD# [001] 58 Phase IIb clinical 58 SUTENT ® 58 refractory gout 58 lorcaserin Phase 58 NO# [002] 58 clevidipine 58 multicenter Phase 58 PROVENGE sipuleucel T 58 volociximab 58 DPP4 inhibitor 58 Actemra 58 blinded randomized placebo controlled 58 tremelimumab 58 refractory NSCLC 58 Huntexil 58 PCK# 58 Capesaris 58 PD LID 58 oral antiviral 58 multiple ascending dose 58 alogliptin 58 Nuvion 58 gemcitabine chemotherapy 58 ACTEMRA 58 denosumab 58 Pirfenidone 58 signal transduction inhibitor 58 LibiGel Phase III 58 aclidinium 58 tasocitinib 58 refractory indolent non 58 BRIM3 58 noninfectious uveitis 58 rhIL 7 58 INTUNIV 58 Pivotal Trial 58 Vectibix